cytochrome c oxidase subunit 6C pseudogene 18Genealiases: []
Q-omics provides the consensus-scored COX6CP18 profile across patient tissues and cancer cell-line models. COX6CP18 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, COX6CP18 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, COX6CP18 RNA expression shows 5,503 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, KIRC, and LSCC as cancer lineages where COX6CP18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COX6CP18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COX6CP18 survival associations across molecular data types. COX6CP18 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COX6CP18 RNA expression–survival associations across cancer types. High COX6CP18 expression shows unfavorable associations in MESO, CESC, KIRP, KIRC and BRCA, but favorable associations in COAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for COX6CP18 RNA expression.
This table summarizes COX6CP18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for COX6CP18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COX6CP18 shows lower tumor expression in KIRC and higher tumor expression in COAD. The KIRC box plot shows higher COX6CP18 RNA expression in normal versus tumor tissue (log2 FC = −0.034, t-test p = .012).
This table shows molecular features associated with COX6CP18 in patient tissues and cancer cell lines. In patient samples, COX6CP18 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
